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The objective of this study was to comprehend the pricing differentiation of essential drugs between 
the local pharmaceutical companies (LPC) and multinational pharmaceutical companies (MNC) of 
Bangladesh. Thirty five (35) essential drug prices were collected from a local drug directory, namely 
Bangladesh National Formulary 2006. The mean and standard deviation of the prices of drugs 
belonging to all therapeutics categories (Anti-infective drugs, Central nervous system, Respiratory 
system, cardiovascular system, gastrointestinal system, Endocrine system drugs, Vitamin, drugs for 
Skin and Analgesic/painkillers) were analyzed. Managers of two multinational companies (MNCs) 
named GlaxoSmithKline Bangladesh Limited Bangladesh and Sanafi Aventis Bangladesh; and three 
local pharmaceutical companies (LPCs) named Square Pharmaceuticals Limited, Beximco 
Pharmaceuticals Limited and Incepta Pharmaceuticals Limited were interviewed after data analysis. A 
wide range of price variations (p < 0.01) between MNC and LPC essential drug products exist. 
Antibiotics have higher prices than drug products belonging to other therapeutic groups. Since 
infectious diseases are the major cause of morbidity and mortality in Bangladesh, the government 
should consider bearing part of the burden of antibiotic manufacturing costs and deliver antibiotics to 
the market at reduced price promoting rational prescribing. Further studies are needed to delve the 
causes of anti-infectives high prices and to propose affordability for treating infectious diseases. This 
study evaluates the present situation of the pharmaceutical marketing and pricing strategies in 
Bangladesh in light of the status of the essential drug market. This study will be helpful to assess 
essential drug affordability, to keep pricing strategies appraised, to advise the drug administration of 
options and to arrange for appropriate levels of public healthcare. 
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INTRODUCTION 
 
The approximate total pharmaceutical market size in 
Bangladesh is about 436 million USD per year of which 
about 95% of the total requirement of medicines is 
created by the local companies and the rest 5% is 
imported. The imported drugs mainly comprise of the 
cancer drugs, vaccines for viral diseases, hormones etc 
(Eskayef Bangladesh Limited website (http://www. skfbd. 
com/index.php?page=25&pid=22)0. 
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There are 246 licensed pharmaceutical factories in 
Bangladesh, six of them are owned by multinational com-
panies producing about 10.4% of the local production. 
Locally produced drugs meet 93.4% of the local drug 
demand in Bangladesh. In the past, and particularly 
during 1980s, the essential drugs list of Bangladesh 
included some 200 products. The list has been enlarged 
in the 1990s (Banglapedia, 2003). 
Bangladesh formulated a National Drug Policy (NDP) in 
1982 (Ahmed, 2007). The Drugs (Control) Ordinance, 
1982, was promulgated subsequently to implement the 
NDP (Directorate of Drugs Administration (DDA), Bangla- 
  
 
 
desh, 2007). The drug policy was enacted to ensure 
procurement, local production, quality control, distribution 
and utilization of drugs under unified legislative and 
administrative control and to provide widest coverage to 
people with the most relevant essential drugs at minimum 
cost. Sixteen criteria were set up in NDP of 1982 to guide 
the evaluation of all registered/licensed pharmaceutical 
products already manufactured in, or imported into 
Bangladesh, as well as the evaluation of all new drugs. 
The first 11 criteria were based exclusively on scientific 
reasoning while number 14 was based on political and 
economic considerations as well: the hope was that multi-
national companies, no longer allowed to manufacture or 
market antacids and oral vitamins, would concentrate on 
producing more useful drugs such as antibiotics and 
other life-saving drugs, and that the ban would also help 
in prevention of monopoly cartels. The remaining four 
criteria (Ahmed M (2007). Effects of regulation on 
pharmaceutical market in Bangladesh. [cited 2007 Apr 
30] Available from 
http://www.pharmadu.net/articlesdetail.php?art=2&pg=1) 
were for the benefit of the local national industries. 
The NDP brought the retail price of drugs down. The 
maximum retail price of drugs was in some cases cut in 
half after the policy was enacted. Before the NDP, eight 
multinational companies (out of 166 licensed companies) 
had about 75 to 80 per cent share of the drug market and 
the prices of multinational drugs were extremely high. 
Many of them abandoned their operations in Bangladesh 
after the NDP. Some multinational factories were sold to 
the local manufacturers. The Pfizer’s pharmaceutical 
plant situated in Mirpur of the capital city of Dhaka was 
bought by a local manufacturer. Pfizer’s plant took the 
new name Renata Limited and it started manufacturing 
and selling drugs under local control. The responsibilities 
of the multinational company ICI and Organon have 
taken over by the local entrepreneur ACI Ltd and Nuvista 
Ltd respectively. The Squib and Hoechst have closed 
their operation in Bangladesh after the National Drug 
Policy in 1982. 
Recent newspaper reports said exaggerated price for 
drugs persists in Bangladesh market. Pharmaceutical 
companies differ on the prices of some drugs by 100 to 
200 per cent claiming quality differences. For example 
ciprofloxacin, a broad spectrum powerful and well 
prescribed popular antibiotic, which has a manufacturing 
cost of Tk 1.6, is sold in the market between Tk 6 - 14 (I 
USD = 68.7 Tk.) (Saad Hammadi, 2008). 
According to the Ministry of Health, Bangladesh, a 
minimum quality standard is set by the Directorate of 
Drug Administration, Bangladesh and the drug prices can 
differ because of the companies’ infrastructures, goodwill 
and its way of practicing the current Good Manufacturing 
Practicing if they maintain a higher quality standard. The 
ministry has also said that any unethical practice in the 
pharmaceutical sector is not within the notice of the 
health ministry (Saad Hammadi, 2008). 
Although 1982’s drug policy recommended the prices  of 
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all drugs be controlled by the drug administration, the 
policy was revised in 1994 selecting 117 essential drugs 
which the government would control. The present study is 
based on these controlled drugs. Reports claimed that 
barely 50 drugs are in practice controlled in the market by 
the government (Saad Hammadi, 2008). 
On the basis of safety, efficacy and minor side effects, 
the World Health Organization suggests the sale of some 
drugs over the counter without the requirement of a 
prescription. Pharmacies in Bangladesh, however, sell 
almost all medicine over the counter regardless of 
legislations. 
The aim of this study is to evaluate the present situation 
of the pharmaceutical marketing and pricing strategies in 
Bangladesh in light of the status of the essential and 
controlled drug market. 
The pharmaceutical companies in Bangladesh are 
mostly formulation industries. Most of the active ingre-
dients and other raw materials are imported from different 
parts of the globe and then manufactured in the plants 
situated in the country. A very few number of active 
ingredients are being produced by the local companies. 
The sources of price differences in this country are the 
costs of raw materials and production technology. A 
study on price differentiation within Bangladesh is neces-
sary to assess essential drug affordability, to keep pricing 
strategies appraised, to advise the drug administration of 
options and to arrange for appropriate level of public 
healthcare. The objective of this study was to 
comprehend the pricing differentiation of essential drugs 
between the local pharmaceutical companies (LPC) and 
multinational pharmaceutical companies (MNC) of 
Bangladesh and correlate them with marketing and sales 
highlights mentioned by top ranking pharmaceutical 
companies of Bangladesh. 
 
 
METHOD 
 
Study population and data collection 
 
Thirty five (35) essential drug prices were collected from a local 
drug directory, namely Bangladesh National Formulary (BDNF) 
2006. For ease of comparison, only oral solid dosage forms were 
taken for study. The mean and standard deviation of the prices of 
essential drugs belonging to all therapeutics categories (Anti-
infective drugs, Central nervous system, Respiratory system, 
Cardiovascular system, Gastrointestinal system, Endocrine system 
drugs, Vitamins, Dermatological drugs for Skin and Analgesics/ 
painkillers) listed in the BDNF were analyzed. Only those drug 
products were selected which were manufactured in Bangladesh, 
marketed by both MNCs and LPCs and had the same dosage 
forms, release profiles, therapeutic effects, etc.  The local pharma-
ceutical companies offering higher number of drugs and dosage 
forms, launching new drugs frequently and regularly. They are sup-
plying drugs to the countries’ largest public and private hospitals, 
exporting drugs to foreign countries which were selected after 
comprehensive literature and data review. Three top ranking com-
panies who scored higher in these criteria were interviewed. The 
world’s leading multinational companies operating in Bangladesh 
were listed. The two multinational companies having highest growth 
and share of market in 2004 as indicated by  the  US  based  maga- 
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Figure 1. Anti-infective drugs: Comparative unit price- LPC vs MNC (Significant difference p < 0.05). 
 
 
 
zine Pharmaceutical Executive were selected for interview. 
Managers of two multinational companies (MNCs) named Glaxo 
Smith Kline (Bangladesh) Limited and Sanafi Aventis (Bangladesh) 
Limited  and three local pharmaceutical companies (LPCs) named 
Square Pharmaceuticals Limited, Beximco Pharmaceuticals Limited 
and Incepta Pharmaceuticals Limited were interviewed after data 
analysis. The managers were asked questions on market prices, 
cause of high or low price and the marketing strategies of those 
manufactured medicines. The interviews were conducted in July - 
September, 2008. The unique strategies and viewpoints they adopt 
for pricing, marketing and selling their products were asked. Each 
interview took about 2 - 3 h. 
Among the various companies, the highest price offered by a 
multinational company and the lowest price offered by a local 
company, having position within top 10 evaluated through current 
ranking procedure were taken for analysis. The top 10 ranking was 
prepared according to the in-house market data of the five 
companies interviewed. The prices were measured in taka value (1 
USD equals 68.7 taka). The price of each unit tablet or capsule was 
considered for analysis. 
 
 
Ethics 
 
The examination committee of Faculty of Pharmacy, University of 
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RESULTS 
 
Two (2) LPC products (Aspirin 300 mg, Chlorpromazine 
25 mg) out of 35 essential drug products had unit price 
higher than MNC products and another 5 MNC and LPC 
essential drug products (Atenolol 50 mg, Glibenclamide, 
Amitriptyline, Griseofulvin and Salbutamol) had exactly 
the same rates. 
Overall, the average price difference between MNCs 
and LPCs was Tk. 0.42 (SD 0.92, min -0.6, max 4.79). 
The values of different parameters such as mean, SD, 
minimum and maximum value indicates a wide range of 
price variations between MNC and LPC products. Overall 
the mean price of MNC drugs was Tk. 1.99 and LPC 
drugs were Tk. 1.57. There is a significant variation 
between the price of MNCs and LPCs (p < 0.01). 
The Figures 1, 2, and 3 presenting a sharp trend of 
price variations among different essential drugs in 
Bangladesh and reflecting that drug price for LPC had a 
much lower price rate than MNC. Moreover, the price 
increases for all drugs were not linear. The price 
difference between LPC and MNC products was compa-
ratively higher for costly items. Comparative three figures 
depicted that the overall price for the anti-infective drugs 
were comparatively higher than any other drugs for both 
MNC and LPC. 
During qualitative data collection, the MNC managers 
explained the reasons of high prices for most of their pro-
ducts. The reasons of higher price stated were exclusive 
sources of raw materials, exclusive production capa-
bilities and exclusive marketing policies. It has been said 
that the cost of raw materials varied significantly between 
those are imported from Asia and those are from Europe.  
The MNCs claimed they have restrictions imposed over 
them by parent companies and therefore they are bound 
to bring raw materials from such sources that are more 
expensive than the sources of LPCs. 
Similarly, the parent MNCs companies strictly maintain 
several expensive features in their production plants 
allover the world, which are not often  maintained  by  the
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Figure 2. Central nervous system, respiratory system, cardiovascular system drugs: comparative unit 
price- LPC vs MNC (Significant difference p < 0.05). 
 
 
 
 
 
Figure 3. Vitamin, drugs for Skin, Gastrointestinal system, Endocrine system and Analgesic/painkillers: 
Comparative unit price- LPC vs MNC (Significant difference p < 0.05) 
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local companies. Some MNC promotional literatures and 
designs are brought from the parent companies that 
require exceptional printing media and technology. The 
promotion officers of MNCs are often sent overseas for 
training.  The MNCs claimed their promotional campaigns 
are more expensive and exceptional than the LPC 
companies. 
The LPCs have admitted their lower prices for their 
marketing strength. Since 1982 the growth of local drug 
production has been accelerated (Eskayef Bangladesh 
Limited website (http://www.skfbd.com/index.php? 
page=25&pid=22). The LPCs also have developed stan-
dard manufacturing facilities. They are exporting drugs to 
a number of countries worldwide. Most of the top LPC 
companies hold ISO certification. Moreover many of them 
were derived from MNCs. The MNC manufacturing and 
marketing practices are therefore retained in them. 
 
 
DISCUSSIONS 
 
Although the MNCs proclaim the exclusivity of their 
manufacturing process and brands and with that reason 
heightened most of their product prices, but still they 
have managed lower prices for some of their brands and 
been dominating in several therapeutic categories with 
 competitive pricing. 
Although the LPCs are generally known as offering low 
prices, they have increased their prices in some 
instances even more than MNCs. Two (2) LPC products 
out of 35 essential drug products had unit price higher 
than MNC products. Those were H1 antihistamines and 
analgesics. These two drugs, that is Aspirin and 
Chlorpromazine are very common OTC drugs. The higher 
price of LPCs here may be explained by the reasons that 
most OTC products are used in low doses and generally 
for short periods. The OTC products generally have lower 
prices (Stan Bernard, 2007). A higher price can ensure 
some degree of profitability here. 
Another 5 MNC and LPC essential drug products had 
exactly similar rates (Figure 2), namely Atenolol 50 mg, 
Glibenclamide, Amitriptyline, Griseofulvin and Salbu-
tamol. These five are all chronic care drug products; they 
are antidiabetic, psychotropic, antifungal, cardiovascular, 
and antiasthmatic drugs. Chronic care products for the 
aging population have been mentioned as the fastest-
growing market of the world (Layne Oliff and Sibyl Shalo, 
2002; Paul, 2003). The major pharma companies of 
Bangladesh, e.g., Beximco and Incepta Pharmaceuticals 
Limited have structured a separate ‘chronic care sales 
team’ out of their 1000 –1200 membered sales force. A 
narrow, but strong and deep focus for chronic care 
market makes the competitors more closely facing one 
another. The price differentiation is therefore minimum 
here. 
Advertisement of drugs in television and newspapers is 
not allowed in Bangladesh. There is no OTC and pre-
scription  only  classification  among  drugs  marketed   in  
 
 
 
 
Bangladesh like that exists in USA. Still the pharma-
ceutical companies have differentiated the promotional 
campaigns of common OTC drugs like analgesics and, 
cold and cough preparations. These OTC products 
packaging is done keeping in mind that these are often 
purchased at patients own discretion like consumer food 
products. The pharmaceutical companies have prepared 
packaging of paracetamol and vitamin C preparations in 
colorful style to attract the patients. These OTC products 
are taken for short periods, purchased in small quantity 
but a large number of populations know them and buy 
without prescription. OTC drugs are even stored at home 
for emergency use. When promoting OTC drugs, the 
companies are more interested about empire building 
and dominating at certain regions in the country. The 
OTC drug promotional campaign is large scale, involving 
retailers to a larger extent than in other product campaigns. 
The per pill profit of OTCs are important as they are 
bought in small quantity. The per pill profit is also very im-
portant in cases of antibiotics which are used for 7 - 14 
days in respiratory tract, skin and soft tissues infections 
etc. Patients often neglect to buy antipsychotic drugs, 
vitamins, analgesics etc. thinking those are unnecessary 
and they can lead a healthy life without those, but they 
rarely neglect antibiotic purchase. Patients are willing to 
buy the full course of antibiotics at a time, since the pre-
scribers explain to them that the disease would recur if 
they do not finish the full course of medicines prescribed. 
Moreover, most of the antibiotics are presented in capsule 
dosage forms, whereas most of the common analgesics, 
antipsychotic and cardiovascular drugs are manufactured 
in white tablet dosage forms, smaller in size than 
capsules. The large colorful capsules of antibiotics 
packaged in equally large blisters impart seriousness in 
the appearance of antimicrobial products. The patients as 
well as rural medical practitioners are impressed by the 
appearance of antibiotics and are eager to buy them. The 
80% of the rural people receive their primary healthcare 
service from rural medical practitio-ners (RMP) in 
Bangladesh (9). They are of friendly attitude, not involved 
in any research work and mostly practicing in rural areas 
where infectious diseases occur more often. Most 
registered allopathic doctors in Bangladesh, even those 
posted in remote areas of the country severely interro-
gate the field officers when they come up with a product 
of higher price. Most of these doctors demand very 
expensive full text articles from world-renowned journals 
for justifying the prescribing information in drug leaflets 
and information brochures. The doctors require full text 
articles for their personal research also and appreciate 
contribution for their visit to overseas medical conferences. 
Since the RMPs are a major contributor to sales of 
antibiotics, who are easy going, the medical information 
officers are fond of working with antibiotics. The medical 
information officers are assigned to report their super-
visors selling of certain value in terms of currency. Most 
companies don’t take notice of the units or therapeutic 
categories sold.  The  medical  information  officers  are  pro- 
  
 
 
moted to higher positions on the basis of money they 
contributed. Since the antibiotics are of higher prices, the 
field officers believe selling of antibiotics will make him 
finish his monthly allocated sales within less time by 
avoiding the painful ventures, like - roaming 18 hours a 
day within hospital compound, following each patient up 
to retail shop and convincing them to buy all the products 
listed in prescription etc. When selling antibiotics to 
doctors of major cities, they are certain, each prescription 
they generated by detailing to doctor will be fully utilized, 
give immediate sales of his products. These same field 
officers are later promoted to the posts of top managers 
and decision makers of pharmaceutical companies after 
years of struggling in the market. Therefore, the pharma-
ceutical companies, in general are appreciative and 
dependent upon sales of antibiotics for reporting an 
impressive sum of sales to their owner. 
The higher and unjustified antibiotic prices of pharma-
ceutical companies are a major concern in the 
subcontinent. Due to high technology dosage forms like 
capsules, pellets etc. and costly active ingredients, the 
antibiotic manufacturing cost may increase, but studies in 
South Asian regions (Vi Shankar et al., 2006; Rataboli 
and Dang, 2007) have pointed out that some companies 
do increase the antibiotics price exorbitantly as per pill 
profit is important in case of antibiotics. Per pill profit is 
not that important in case of chronic care products since 
those are used for a long time. People of chronic care 
diseases like cardiovascular, diabetic, neurologic 
diseases mostly visit allopathic doctors in practicing in 
major cities. Not all regions of the country have diabetic 
hospitals and those chronic diseases require up to date 
and advanced knowledge for management that the RMPs 
can’t offer. Therefore the promotion of chronic care 
products consists of mainly organizing frequent 
Continuing Medical Education programs for doctors and 
knowledge sharing. 
In this study it has been found that price variation 
among companies is higher in case of OTC products and 
antibiotics. This study finding implicate that price variation 
is minimum in case of chronic care products. It can be 
inferred that the companies are fixing prices considering 
per pill profit even under the strict price regulations by 
government. 
Antibiotics have higher prices than drug products 
belonging to other therapeutic groups. Since infectious 
diseases are the major cause of morbidity and mortality 
in Bangladesh, the government should consider bearing 
part of the burden of antibiotic manufacturing costs and 
deliver antibiotics to the market at reduced price. The 
contribution of government can also reduce the variation 
of antibiotic prices among companies that increase the 
prices of antibiotics exorbitantly in excuse of higher raw 
material and manufacturing cost of antibiotics. New gene-
ration antibiotics like cephalosporins and quinolones are not 
included within the essential and controlled drugs list. 
Existing antibiotics within the essential drug list have 
been reported to be affordable by 80% of  the  population  
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of Bangladesh (Government of Bangladesh and United 
Nations (UN) Country Team. Millennium development 
goal (MDG) progress report 2005). Further studies are 
needed to delve the causes of new generation anti-
infectives high prices and to propose affordability for 
treating infectious diseases. 
The MNCs are still claiming higher prices of drugs in 
Bangladesh, even though NDP has executed regulations 
to reduce price differentiations among companies in Ban-
gladesh. Several literatures released during the eighties 
and nineties (Ahmed, 2007; Kazi Zawad, 1985) criticized 
high price of MNC drugs. It was said that multinational 
companies purchase raw materials from their parent 
companies by foreign currency and cause a destroying 
effect on local economy (Ahmed, 2007). Multinational 
companies produced documents showing high raw 
materials’ price and low income in favour of their high 
price. By this way, Bangladesh government deprived 
from huge amount of taxes. For instances, in 1979, Pfizer 
purchased tetracycline from Hong Kong Pfizer Labora-
tories at a price of US$ 80.36 per Kg. Where as Pharma-
desh (a local Pharmaceutical company) purchased the 
same tetracycline from Yugoslavia at a price of only US$ 
42 per Kg.  These arguments were presented before the 
enactment of NDP in 1980; still today multinational 
companies speak of their high cost of raw materials. But 
in recent times, no criticism of multinational prices has 
been observed in newspapers and other media of 
Bangladesh. It indicates the present status of MNC high 
prices are staying within tolerable limit. This study aimed 
to comprehend the underlying issues of drug marketing 
and sales that affect public healthcare. The issues like 
higher prices of several LPC drugs are worthy noting. 
While all other multinational essential drug brands offer 
higher prices than LPC products, the lower prices of the 
world renowned multinational brands like Disprin and 
Largactil in Bangladesh can suggest an interesting facet 
of strategic brand management. 
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